1. The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma 
Hala Faragalla, Youssef M. Youssef, Andreas Scorilas, Bishoy Khalil, Nicole M.A. White, Salvador Mejia-Guerrero, Heba Khella, Michael A.S. Jewett, Andrew Evans, Zsuzsanna Lichner, Georg Bjarnason, Linda Sugar, Magdy I. Attalah, George M. Yousef 
The Journal of Molecular Diagnostics 
Volume 14, Issue 4, Pages (July 2012)
DOI: /j.jmoldx
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

2. Figure 1
Expression of miR-21 in healthy kidney, the different subtypes of RCC, and oncocytoma. Statistically significant higher levels of expression are seen in both ccRCC and pRCC subtypes compared with healthy kidney and both chRCC and oncocytoma (P < 0.001). P values were calculated by the Kruskal-Wallis test.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

3. Figure 2
ROC analyses showing the significance of miR-21 expression levels in the distinguishing clear cell or papillary RCC from noncancerous kidney tissues. For ccRCC and pRCC versus healthy: AUC, 0.687; 95% CI, to 0.795; P =
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

4. Figure 3
miR-21 can distinguish clear and papillary subtypes of RCC from chromophobe RCC and oncocytoma with high accuracy. By using a cutoff equal to 3.7 relative quantification units, the specificity is 90%, with a sensitivity of 83%. For ccRCC and pRCC versus chRCC and oncocytoma: AUC, 0.886; 95% CI, to 0.955; P =
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

5. Figure 4
Kaplan-Meier DFS plot comparing miR-21 expression (positive or negative) in patients with RCC. The miR-21–negative group shows more patients with a higher cumulative DFS survival rate, compared with the miR-21–positive group (P = 0.008).
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

6. Figure 5
Kaplan-Meier overall survival plot comparing miR-21 expression (positive or negative) in patients with RCC. miR-21–positive patients show a statistically significant shorter overall survival compared with those who are miR-21 negative (P = 0.031).
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions